Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 30Small Cell Lung Carcinoma 13Recurrence 3Melanoma 3Lung Neoplasms 3Advanced Lung Cancer 3NSCLC 2Lymphoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Treatment-naive Advanced Non-small Cell Lung Cancer 1Thoracic Neoplasms 1Stage IB-IIIB NSCLC 1Small Cell Lung Cancer Limited Stage 1Sarcoma 1SCLC, Extensive Stage 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Ovarian Neoplasms 1Non-small Lung Cancer 1Non Squamous Non Small Cell Lung Cancer 1Non Small Cell Lung Cancer Recurrent 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Lung Diseases 1Local Advanced Non-small Cell Lung Cancer 1Liver Neoplasms 1Kidney Neoplasms 1

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High-Risk Resectable NSCLC × toripalimab × Thoracic × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡